Evidence map›Paper›PMID 40080303›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Evaluation of imipenem-relebactam susceptibility testing in carbapenem resistant Pseudomonas aeruginosa: comparison of sensititre microplates, disc diffusion, and MTS gradient strips with broth microdilution.

Adrien Biguenet, Léa Devoos, Julie Rousselot, Maxime Bour, Damien Fournier, Katy Jeannot

Abstract readComparative StudyEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Performance evaluation of antimicrobial susceptibility testing methods for ceftazidime-avibactam and imipenem-relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adrien BiguenetLaboratoire de Bactériologie, Centre Hospitalier Universitaire de Besançon, Besançon, France.
Léa DevoosLaboratoire de Bactériologie, Centre Hospitalier Universitaire de Besançon, Besançon, France.
Julie RousselotLaboratoire associé au Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
Maxime BourLaboratoire associé au Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
Damien FournierLaboratoire de Bactériologie, Centre Hospitalier Universitaire de Besançon, Besançon, France.
Katy JeannotLaboratoire de Bactériologie, Centre Hospitalier Universitaire de Besançon, Besançon, France. katy.jeannot@univ-fcomte.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Four commercial tests EUMDROXF

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCarbapenemsImipenemPseudomonas aeruginosaDisk Diffusion Antimicrobial TestsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsPseudomonas InfectionsAnti-Bacterial AgentsAzabicyclo CompoundsCarbapenemsImipenemrelebactam

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.